Acute Pulmonary Embolism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Acute Pulmonary Embolism Market Outlook
Thelansis’s “Acute Pulmonary Embolism
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Acute Pulmonary Embolism treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Acute
Pulmonary Embolism Overview
Acute
pulmonary embolism is a common clinical challenge due to its varied clinical
manifestations. It occurs when a thrombus disrupts blood flow in the pulmonary
artery or its branches, typically originating from deep vein thrombosis (DVT)
in the lower extremities. Consequently, risk factors for pulmonary embolism
mirror those of DVT, as elucidated by Virchow’s triad: hypercoagulability,
venous stasis, and endothelial injury. Pulmonary embolisms result from
embolized clots entering the pulmonary circulation, often appearing as multiple
clots with a predilection for the lower lung lobes and bilateral involvement.
While Brain Natriuretic Peptide (BNP) elevation has limited diagnostic utility
in suspected PE cases, anticoagulation remains the cornerstone of treatment.
Low-molecular-weight heparin (LMWH), fondaparinux, or unfractionated heparin
(UFH) are viable options for anticoagulation in acute PE management.
Furthermore, Vena Cava Filters serve to obstruct emboli passage, preventing
their entry into the pulmonary circulation.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment